S4 is andarine

We've found that according to the scientific database used by our third party testing facility S4 had been incorrectly identified and listed as ostarine. Because ostarine (MK-2866) and andarine (S4) have very similar molecular structures and properties, this misidentity has occured often, even so on the academic level - as illustrated by the fact the even the scientific database which the lab was using had S4 misidentified. Moving forward, to be clear, we sell S4. S4 is andarine, chemically: S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide.

Several published articles are available to learn more about andarine and its use as a predominant model compound of SARMs.

An updated COA will soon be available.

Thanks everyone!

RUI
 
thanks for posting this, but i'm still hella confused.. I've had solid gains using your S4, RUI, but is andarine similar to ostarine?

So what the hell is sarmsearch and others selling? And is S4 really andarine? Also, are there any toxicity issues to be worried about with andarine? I've haven't really experienced too much in terms of occular issues, but i've only been running it at 25mgs/ed.

Any more info would be MUCH appreciated..
 
Thanks for clearing things up!! I really appreciate it...

There is a lot of confusion out there on the net about S-4/andarine,s-1 and ostrine...
 
thanks for posting this, but i'm still hella confused.. I've had solid gains using your S4, RUI, but is andarine similar to ostarine?

So what the hell is sarmsearch and others selling? And is S4 really andarine? Also, are there any toxicity issues to be worried about with andarine? I've haven't really experienced too much in terms of occular issues, but i've only been running it at 25mgs/ed.

Any more info would be MUCH appreciated..

I've looked and looked for any other sides associated with s-4 other then the vision issues. I can t find any....

There could always be long term sides we dont know about tho...
:dunno:

BTW- I'd up the dose 25mg is to low...50-75mg is the way to go from what I've read.
 
Do we all agree that Andarine's geenric name is acetamidoxolutamide ?

S.B.C., Yes, that is correct.



Mr.Happy said:
sarms s4 is acetamidoxolutamide

Mr.Happy, andarine is S4. It seems you're infering S4 and andarine are different compounds. Just making sure you understand that is not the case. There has been much confusion on this, even at the academic level.




TO BE CLEAR:

S4 = S-4 = andarine = (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide)
 
Last edited:
Good read......................


3602 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12 Award Address
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)

Section 1.5.2. Nonsteroidal AR Agonists. The Propionamides.

..the resulting compound known
in the literature as S-4 and in press releases as andarine (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide) was
shown to possess SARM activity and allowed the pharmacodynamic exploration of this novel class of drugs.

Section 2.1.7. Andarine, the Prototypical Full Efficacy SARM.

Andarine was a SARM that served as the predominant model compound early in the development of the SARM field. Many of the landmark studies with andarine served as proofs-of-concept in the SARM field (e.g., concomitant myo- and osteoanabolism in the absence of VP proliferation, musculoskeletal performance enhancement, etc.). Preclinical characterization of andarine demonstrated high binding affinity for AR (Ki ) 4 nM) and ideal pharmacokinetics (complete oral bioavailability, plasma half-life consistent with daily oral dosing in rats and dogs) with no cross-reactivity with the other nuclear receptors. Myoanabolism was demonstrated in terms of maintenance and restoration of LA weight and restoration of soleus muscle strength in castrated rats. Likewise, osteoanabolism was observed in maintenance and restorative modes in male and female rats with improvements in biomechanical strength, cumulatively demonstrating musculoskeletal performance enhancement. The anabolic effects were also observed at the level of the entire organism as revealed by favorable body composition changes. Importantly, these anabolic effects were tissue-selective when compared to androgenic tissue and HPG axis effects, establishing andarine as a prototypical preclinical SARM. The peripheral and selective anabolic preclinical pharmacodynamic profile of andarine seemed highly promising and stimulated us to pursue landmark clinical trials of the SARMs, andarine and Ostarine. Although phase I studies with andarine were successful with no deficiencies noted , Ostarine was selected for advanced clinical development based on corporate strategy. Readers are cautioned to note that the name Ostarine is often mistakenly linked to the chemical structure of andarine. The chemical structure of Ostarine has not been publicly disclosed. The authors are unable to provide additional information. Collectively, these preclinical and clinical studies have provided the foundation for the massive body of SARM characterizations that are now published and patented (discussed below). Importantly, many of these pharmacodynamic observations have proven to be typical of subsequently published chemodiverse SARMs, as discussed in section 3.
 
Good read......................


3602 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12 Award Address
Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit - Journal of Medicinal Chemistry (ACS Publications)

Section 1.5.2. Nonsteroidal AR Agonists. The Propionamides.

..the resulting compound known
in the literature as S-4 and in press releases as andarine (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide) was
shown to possess SARM activity and allowed the pharmacodynamic exploration of this novel class of drugs.

Section 2.1.7. Andarine, the Prototypical Full Efficacy SARM.

Andarine was a SARM that served as the predominant model compound early in the development of the SARM field. Many of the landmark studies with andarine served as proofs-of-concept in the SARM field (e.g., concomitant myo- and osteoanabolism in the absence of VP proliferation, musculoskeletal performance enhancement, etc.). Preclinical characterization of andarine demonstrated high binding affinity for AR (Ki ) 4 nM) and ideal pharmacokinetics (complete oral bioavailability, plasma half-life consistent with daily oral dosing in rats and dogs) with no cross-reactivity with the other nuclear receptors. Myoanabolism was demonstrated in terms of maintenance and restoration of LA weight and restoration of soleus muscle strength in castrated rats. Likewise, osteoanabolism was observed in maintenance and restorative modes in male and female rats with improvements in biomechanical strength, cumulatively demonstrating musculoskeletal performance enhancement. The anabolic effects were also observed at the level of the entire organism as revealed by favorable body composition changes. Importantly, these anabolic effects were tissue-selective when compared to androgenic tissue and HPG axis effects, establishing andarine as a prototypical preclinical SARM. The peripheral and selective anabolic preclinical pharmacodynamic profile of andarine seemed highly promising and stimulated us to pursue landmark clinical trials of the SARMs, andarine and Ostarine. Although phase I studies with andarine were successful with no deficiencies noted , Ostarine was selected for advanced clinical development based on corporate strategy. Readers are cautioned to note that the name Ostarine is often mistakenly linked to the chemical structure of andarine. The chemical structure of Ostarine has not been publicly disclosed. The authors are unable to provide additional information. Collectively, these preclinical and clinical studies have provided the foundation for the massive body of SARM characterizations that are now published and patented (discussed below). Importantly, many of these pharmacodynamic observations have proven to be typical of subsequently published chemodiverse SARMs, as discussed in section 3.


Did you forget to add the " (8, " ( you can see on PAGE 4 on link below ) before (S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
trifluoromethylphenyl)propionamide)

Is all here:

2008 Medicinal Chemistry DiVision Award Address

Thanks

Chavo
 
Last edited:
funny i posted this about a while back in another thread, quoting a response from RUI, and other information from another board about andarine vs ostarine and a mod deleted it? :scratchhe:dunno: guess its ok now though so feel free to ask me for my source?

anyways.. to my knowledge there still hasn't been a human clinical trial of either andarine or ostarine, and i was simply wanting to point out to anyone that there is so little known about this particular SARM, and research was stopped by GTx/Merck because of adverse side effects:

Serious occular events were seen with S-4, due to a known metabolism problem. These problems are NOT limited to occular issues - just that occular issues are some of the first seen.

Again feel free to PM me for sources!
 
I didn't want to start another thread, seems the thread on Sarms Research is closed. Just curious. Sarms S-4 is known by it's chemical name Acetamidoxolutamide and following some threads on this forum1 indicates that it's Andarine. Is this a a lower discontinued grade? Would it be best to wait for the MK-2866 Ostarine (GTX Inc. phase 2 trial)?
 
glad I bumped into this thread I've been reading up on uniquemicals S4 and this thread has given me me stuff to read through.looks like I still have more research to do.
 
Back
Top